Literature DB >> 21289366

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

H A Azim1, E de Azambuja1, M Colozza2, J Bines3, M J Piccart4.   

Abstract

Breast cancer is the most common malignant tumor affecting women. Adjuvant systemic therapies have been shown to have a significant impact on reducing the risk for breast cancer recurrence and overall mortality. Chemotherapy remains an important and frequently used treatment option in the adjuvant setting, and the associated short-term adverse events are very well described. However, there is insufficient information regarding the long-term sequelae of most chemotherapeutic agents. In this review, we describe different potential long-term adverse events associated with adjuvant chemotherapy in breast cancer, with a particular focus on long-term cardiac toxicity, secondary leukemia, cognitive function, and neurotoxicity. In addition, we discuss the effect of adjuvant chemotherapy on fertility and sexual function of young breast cancer patients. These adverse events are frequently overshadowed by the well-demonstrated clinical efficacy and/or reassuring short-term safety profiles of the different chemotherapy regimens commonly used today. We believe that a proper understanding and appreciation of these adverse events will enable us to refine our strategies for managing breast cancer. The fact that adjuvant chemotherapy is often given to patients who might not really need it urges us to consider the whole spectrum of chemotherapy risks versus benefits to maximize benefit without compromising quality of life.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289366     DOI: 10.1093/annonc/mdq683

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  82 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

Review 2.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

3.  Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy.

Authors:  Alexandre Chan; Christy Chen; Joen Chiang; Sze Huey Tan; Raymond Ng
Journal:  Support Care Cancer       Date:  2011-08-05       Impact factor: 3.603

4.  Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

Authors:  Carolyn Taylor; Candace Correa; Frances K Duane; Marianne C Aznar; Stewart J Anderson; Jonas Bergh; David Dodwell; Marianne Ewertz; Richard Gray; Reshma Jagsi; Lori Pierce; Kathleen I Pritchard; Sandra Swain; Zhe Wang; Yaochen Wang; Tim Whelan; Richard Peto; Paul McGale
Journal:  J Clin Oncol       Date:  2017-03-20       Impact factor: 44.544

5.  Induction of Apoptosis in Human Breast Cancer MCF-7 Cells by a Semi-Synthetic Derivative of Artemisinin: A Caspase-Related Mechanism.

Authors:  Leila Jamalzadeh; Hossein Ghafoori; Mahmoodreza Aghamaali; Reyhaneh Sariri
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

6.  Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance.

Authors:  Joseph R Carver; Dava Szalda; Bonnie Ky
Journal:  Semin Oncol       Date:  2013-04       Impact factor: 4.929

7.  Breast cancer morbidity: questionnaire survey of patients on the long term effects of disease and adjuvant therapy.

Authors:  Stefan Feiten; Jan Dünnebacke; Jochen Heymanns; Hubert Köppler; Jörg Thomalla; Christoph van Roye; Diana Wey; Rudolf Weide
Journal:  Dtsch Arztebl Int       Date:  2014-08-04       Impact factor: 5.594

8.  Long-term follow-up for cardiovascular disease after chemotherapy and/or radiotherapy for breast cancer in an unselected population.

Authors:  L M Boerman; A J Berendsen; P van der Meer; J H Maduro; M Y Berger; G H de Bock
Journal:  Support Care Cancer       Date:  2014-03-02       Impact factor: 3.603

9.  Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Authors:  Fernando Souza-Fonseca-Guimaraes; Stephen J Blake; Amani Makkouk; Cariad Chester; Holbrook E Kohrt; Mark J Smyth
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

10.  Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.

Authors:  Andrew J Epstein; Yu-Ning Wong; Nandita Mitra; Anil Vachani; Sakhena Hin; Lin Yang; Aaron Smith-McLallen; Katrina Armstrong; Peter W Groeneveld
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.